Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016)

This is the latest version of this eprint.

Moreau, P, van de Donk, NWCJ, San Miguel, J et al. (17 more authors) (2016) Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016). Drugs, 76 (9). pp. 989-990. ISSN 0012-6667

Metadata

Authors/Creators:
  • Moreau, P
  • van de Donk, NWCJ
  • San Miguel, J
  • Lokhorst, H
  • Nahi, H
  • Ben-Yehuda, D
  • Cavo, M
  • Cook, G
  • Delforge, M
  • Einsele, H
  • Zweegman, S
  • Ludwig, H
  • Driessen, C
  • Palumbo, A
  • Facon, T
  • Plesner, T
  • Dimopoulos, M
  • Sondergeld, P
  • Sonneveld, P
  • Mateos, M-V
Dates:
  • Published (online): 20 May 2016
  • Published: June 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 21 Dec 2016 10:20
Last Modified: 22 Dec 2016 10:48
Published Version: http://doi.org/10.1007/s40265-016-0590-3
Status: Published
Publisher: Springer
Identification Number: https://doi.org/10.1007/s40265-016-0590-3
Related URLs:

Available Versions of this Item

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)